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A COST-MINIMIZATION STUDY TO DETERMINE 
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OBJECTIVE: This study is conducted to determine the
economic impact of the addition of a new diabetic agent,
Glucovance (metformin/glyburide) to a county hospital
system with over 21,000 diabetic patients. METHODS:
A cost minimization analysis between Glucovance and
metformin plus any of the sulfonylureas is conducted.
Initially, a database of all diabetic patients in the county
hospital system is created to determine total number of
patients who are being treated with metformin alone and
in combination with other sulfonylureas, glipizide XL,
generic glipizide, glyburide, and glimepiride. Next, the
cost difference between treating with Glucovance alone
or as a dual therapy with both metformin 500mg plus the
most common dose of each sulfonylurea is calculated to
determine the incremental cost savings over a year’s time
of therapy. Only the direct costs of the drugs involved are
utilized in this study. RESULTS: The results indicate that
if all of the 6,622 patients who are on dual therapy with
both metformin 500mg and a usual maintenance dose of
a sulfonylurea drug are switched to the new combination
product, the county system can save over half a million
dollars ($555,566.00) in a year, in direct drug costs alone.
CONCLUSION: These results illustrate that there is an
economic incentive to add the new combination product
to the formulary. However, future cost-effectiveness stud-
ies are needed to determine the impact of this decision
both in terms of clinical and economic outcomes.
PDB6
AN EARLY LOOK AT TZD USE AMONG TYPE 2 
DIABETES PATIENTS
Schabert VF1, Guo M2, Conklin JE1, Neslusan CA2
1The MEDSTAT Group, Santa Barbara, CA, USA; 2R.W. 
Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
OBJECTIVE: One of the newest drug classes used in the
treatment of type-2 diabetes is the thiazolidinediones
(TZDs). TZDs enhance insulin action in insulin-depen-
dent tissues without stimulating insulin secretion. These
drugs are used both as monotherapy and in combination
with other anti-diabetic pharmacotherapies. Two TZDs
are currently on the market, rosiglitazone and pioglita-
zone. Both of these compounds were approved in the US
mid-year 1999. This study examines the patient charac-
teristics, drug use, and resource utilization of individuals
treated with a TZD in the first year following approval.
METHODS: Patients who received at least one prescrip-
tion for rosiglitazone or pioglitazone were selected from
over 2.3 million employees, retirees, and dependents in
the MarketScan® databases. Health plan enrollment
data, medical claims, and pharmacy claims were used to
construct the final sample. Descriptive information is pre-
sented on patient demographics, inpatient, outpatient
and prescription drug use. Comparisons between these
variables across the different therapy groups (e.g., mono-
therapy versus combination therapy) were made using
appropriate statistical tests. RESULTS: 18,801 patients
received at least one prescription for rosiglitazone or pi-
oglitazone during the study period. Mean age is 60.0
years (SD  11.6 years), including 6,510 who were 65 or
older. The sample is almost evenly split between males
and females (52.3% and 47.7%, respectively). 54.9%
(10,324) of the patients had at least three months follow-
up available. Of these, 6.3% (655) were hospitalized
within three months of TZD initiation. Patients filled
other types of diabetes medications after initiating ther-
apy with a TZD—28.8% (n  5,417) insulin, 52.0%
(n  9,776) sulfonylureas, 39.8% (n  7,475) met-
formin, and 7.1% (n  1,340) other types of diabetes
drugs. CONCLUSIONS: Additional TZD-type com-
pounds are being developed. This study provides an early
look at the characteristics and subsequent outcomes of
patients who are being prescribed this important new
type of therapy for diabetes.
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OBJECTIVE: To estimate the lifetime benefits and costs of
intensive insulin therapy for type 2 diabetes mellitus (2DM),
cost-effectiveness analysis was carried out. METHODS:
Cost-effectiveness analysis (CEA) and cost-utility analysis
(CUA) were carried out to estimate the lifetime benefits
and costs of intensive insulin therapy (IIT) for 2DM. A
Markov model base on a randomized controlled trial
(Kumamoto Study) was developed. As a comparator,
conventional therapy (CV) was used. A societal viewpoint
was adopted for the estimation of costs, and both direct
and indirect costs were evaluated. A Monte Carlo simula-
tion was done to evaluate a confidence interval of cost-
effective or cost-utility ratio. Quality of life (utility) was
measured by a time-trade off method among 2DM pa-
tients. RESULTS: At lifetime follow-up among 40 years
of men, expected life years (28.7 years) for IIT were
longer than those (26.5 years) for CT. On the other hand,
expected costs ($106,500) for ITT were higher than those
($95,600). The incremental cost per life-year gained for
IIT was $3,020 (discount rate of cost and effectiveness:
5%). The incremental cost per QALY gained was $3,270.
Sensitivity analysis for age, costs, and health outcomes
confirmed robustness of these results. CONCLUSION:
Over lifetime, IIT for 2DM not only reduces complica-
tions, but also improves QOL and increases length of life.
From a societal perspective, efficiency of IIT is consider-
ably high.
